THERAPY DOSSIER · th-f2733662e03d

PJ34 (N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide)

Drug · No confident ChEMBL match; known PARP-1 inhibitor (research tool)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; known PARP-1 inhibitor (research tool)
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25668593 ↗2015Reported benefit

Protective actions of PJ34, a poly(ADP-ribose)polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice.

MouseTBIControlled cortical impactBALB/cMaleIntraperitoneal10 mg/kg5 min and 8 h after controlled cortical impact

Model: Controlled cortical impact traumatic brain injury

PJ34 attenuated blood-brain barrier permeability and brain oedema at 6 and 24 h, reversed NF-kappaB up-regulation, lowered myeloperoxidase activity and matrix metalloproteinase-9, increased tight junction and basal lamina proteins, and reduced neurological deficit, contusion volume and neuronal cel…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…